计算机检索PubMed、Medline、Web of Science、CBM、CNKI、VIP、Wanfang Data数据库，搜集喜炎平注射液联合抗生素药物对比单用抗生素治疗成人社区获得性肺炎（CAP）疗效和安全性的随机对照试验（RCT），检索时限均为建库至2017年8月。由2位研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用RevMan 5.3软件进行Meta分析。共纳入18个RCT，共入1 924例患者。Meta分析结果显示，与抗生素单用相比，喜炎平注射液联合抗生素治疗能提高成人CAP的临床疗效[RR=1.20，95%，CI（1.15，1.25），P<0.000 01]，同时能改善患者咳嗽等症状和缩短患者退热时间、住院治疗时间。在安全性方面，单用抗生素组，发生不良反应26例，不良反应主要为胃肠道反应、头晕、皮疹、静脉炎等，程度较轻，一般不经治疗可自愈。而喜炎平注射液联合抗生素治疗CAP发生了30例不良反应，反应类型和程度与单用抗生素基本一致。喜炎平注射液联合抗生素治疗CAP能提高临床疗效，改善CAP患者临床症状，其安全性尚可。受纳入研究数量和质量的限制，上述结果需要更多研究予以证实。

To electronically search databases including PubMed, MEDLINE, Web of Science, CBM, CNKI, VIP, Wanfang Data for randomized controlled trials (RCTs) of Xiyanping Injection for adult community acquired pneumonia patients from inception to August, 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then RevMan 5.3 software was used for data analysis. Seventeen RCTs involving 1924 patients with adult community acquired pneumonia were included. The results of meta-analysis showed that Xiyanping Injection combined with antibiotic group was superior to the antibiotic drugs group (RR=1.20, 95% CI 1.15 to 1.25, P < 0.000 01) in treatment adults with community acquired pneumonia. At the same time, it can improve the symptoms of cough and shorten the duration of fever and the duration of hospitalization. In terms of safety, there were 26 cases of adverse reactions in the antibiotic group. The primary adverse reactions were gastrointestinal reaction, dizziness, rash, and phlebitis, and reactions were mild and self-healing. There are 30 adverse reactions cases in the combination group, and the types and levels of reaction are same as antibiotic group. Moreover, the current evidence showed that the combination of Xiyanping Injection and conventional antibiotic drugs in the treatment of community acquired pneumonia may significantly improve the curative effect compared with only antibiotics. Rare adverse reactions occurred and safety evaluation was acceptable. However, due to the low methodological quality of the enrolled studies, more clinical research is needed to further verify the results of this work.

国家“重大新药创制”科技重大专项（2014ZX0921005-138）；重大疾病的防控策略、诊疗规范及效果评价研究（2015BAI12B00）